SCHEMBL9265684

SCHEMBL9265684

CC(=O)Cc1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.56
LTA4H P09960 1/20 0.56
POLB P06746 2/20 0.51
HRH3 Q9Y5N1 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
VNN1 O95497 1/20 0.47
NLRP3 Q96P20 1/20 0.47
ACACB O00763 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
EPHX1 P07099 1/20 0.46
FAAH O00519 1/20 0.46
MAPK8 P45983 1/20 0.45
BCL2L1 Q07817 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7983265 0.95 POLB (0.56) EPHX2LTA4HPOLBHRH3MEN1
SCHEMBL9269591 0.88 LTA4H (0.52) EPHX2LTA4HPOLBNLRP3
SCHEMBL10774498 0.86 POLB (0.66) EPHX2LTA4HPOLBMEN1KMT2A
SCHEMBL27028196 0.85 EPHX2 (0.60) EPHX2LTA4HHRH3MEN1KMT2A
SCHEMBL27237496 0.84 MEN1 (0.66) EPHX2LTA4HPOLBHRH3MEN1
SCHEMBL9266226 0.83 LTA4H (0.56) EPHX2LTA4HPOLBMEN1KMT2A
SCHEMBL22323751 0.83 EPHX2 (0.71) EPHX2POLBMEN1KMT2ASMN1; SMN2
SCHEMBL27028195 0.81 POLB (0.58) EPHX2LTA4HPOLBHRH3MEN1
SCHEMBL9269526 0.81 POLB (0.56) EPHX2LTA4HPOLBKMT2ASMN1; SMN2
SCHEMBL6618984 0.80 EPHX2 (0.48) EPHX2LTA4HHRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111630031-B Process for producing quinolin-4 (1H) -one derivative 日本化药株式会社 2024-03-12 CN disclosed
US-11267787-B2 Method for producing quinolin-4(1H)-one derivative NIPPON KAYAKU CO., LTD (JP) 2022-03-08 US disclosed
US-20210070710-A1 METHOD FOR PRODUCING QUINOLIN-4(1H)-ONE DERIVATIVE NIPPON KAYAKU CO., LTD. (JP) 2021-03-11 US disclosed
CN-111630031-A Process for producing quinolin-4 (1H) -one derivative 日本化药株式会社 2020-09-04 CN disclosed
US-5403934-A Heterocyclic compounds BURROUGHS WELLCOME CO. (US) 1995-04-04 US disclosed
WO-1991013873-A1 HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-19 WO disclosed
EP-0447164-A1 Heterocyclic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11267787-B2 Method for producing quinolin-4(1H)-one derivative NQO2, AKR7A2, KEAP1 EPHX2 1198/4885LTA4H 127/4885POLB 3585/4885
US-20210070710-A1 METHOD FOR PRODUCING QUINOLIN-4(1H)-ONE DERIVATIVE NQO2, AKR7A2, KEAP1 EPHX2 1198/4885LTA4H 127/4885POLB 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.